CMC readiness means you can prove your biotech product can be made, tested, controlled, supplied, and supported through the next value‑creating stage without avoidable manufacturing surprises. Before Series B, you need to fix the gaps that make investors doubt scale-up, quality, supply, regulatory timing, or clinical continuity.
A strong scientific story can still lose funding momentum if the manufacturing story is thin. Series B investors are usually underwriting the path from early promise to clinical execution, and Chemistry Manufacturing and Controls(CMC) is where that path often becomes expensive, slow, or uncertain. This article shows what to fix, what to document, and how to make CMC a funding strength rather than a diligence liability.
Why Series B Investors Now See CMC Readiness As The Readiness Test
By Series B, investors are no longer looking only at the biology, mechanism, animal data, or first clinical signal. They want to know whether the product can be manufactured at the right quality, in the right quantity, on a timeline that supports the clinical plan. If your process works only in a research setting, the investor sees future delay risk. If your assays are still changing, the investor sees comparability risk.
The concern is not theoretical. The United States Food and Drug Administration (FDA) Office of Pharmaceutical Quality reported that 38% of first-cycle New Drug Application (NDA) complete response letters included CMC-related deficiencies. L.E.K. Consulting also reported that many biotech executives experienced CMC-related funding delays, and investors ranked CMC readiness as a top factor in Series B evaluation. The pattern is direct: weak CMC can reduce valuation, slow diligence, or stop a deal near the term-sheet stage.
Your goal is not to look like a commercial manufacturing organization before Series B. Your goal is to show that the CMC plan matches the stage of the asset, that the known risks are controlled, and that the next clinical milestone has a credible supply path. Investors can accept open work. They get nervous when the team cannot define the work, cost it, sequence it, or explain the regulatory path.
Fix No Viable, Scalable Manufacturing Process
The first fix is your manufacturing process. If the process still depends on one scientist’s hands, undefined hold times, low-yield steps, or equipment that cannot transfer to a Contract Development and Manufacturing Organization (CDMO), it is not Series B-ready. Investors want evidence that your process can move beyond lab-scale without breaking quality, yield, cost, or timing. You do not need final commercial scale, but you do need a credible scale-up path.
Start by documenting the current process map from raw material receipt through release. Identify unit operations, process parameters, yields, failure points, in-process controls, and known sensitivities. If the product is a biologic, cell therapy, gene therapy, peptide, small molecule, or complex formulation, the exact risk profile will differ, but the investor question stays the same: can this process make consistent material for the next trial? A vague answer creates a diligence gap.
You should also define the manufacturing version that supports the next clinical step. That means knowing which changes are planned before the next batch, which changes can wait, and which changes may trigger comparability work. If tech transfer is pending, your data room should include the transfer plan, responsibilities, batch records, equipment assumptions, and open decisions. A manufacturing process becomes fundable when it is written, measured, transferable, and tied to the clinical supply plan.
Fix Weak Analytical Methods & Specifications
The second fix is your analytical control package. CMC readiness depends on assays that can identify the product, measure quality attributes, detect impurities, support stability work, and guide release decisions. If methods are exploratory, poorly qualified, or disconnected from product risk, investors will question every batch result. Weak methods make even good manufacturing data harder to trust.
Before Series B, review every method against its intended use. Some methods may only need development or qualification at this stage, not full validation. That distinction matters, but it must be intentional and documented. Your team should be able to explain which assays support release, which support characterization, which support process development, and which will mature before later-stage studies.
Specifications also need discipline. A specification that is too loose may not protect product quality, and a specification that is too tight may create unnecessary batch failure risk. Investors will look for a rationale tied to batch history, method capability, safety, potency, purity, identity, and stability. If the specification story is still immature, say what data will tighten it and when that data will be available.
Fix The Absence Of A Good Manufacturing Practice-Aligned Quality System
The third fix is your quality system. Good Manufacturing Practice (GMP) alignment does not mean you need a large quality department before Series B. It means you have the basic controls needed to make clinical material reliably and to manage deviations, changes, documentation, vendors, training, and release decisions. Investors see quality gaps as clinical supply risk. Regulators may see them as product control risk.
A startup often grows faster than its documentation. Process development teams move quickly, experiments change, and decisions live in slide decks or email threads. That speed helps research, but it can damage CMC readiness if no one can reconstruct why a process changed, why a batch was accepted, or how a vendor was approved. Your quality system should make the product history auditable without slowing every decision to a crawl.
Before fundraising, prioritize quality controls that investors will expect to see. These include document control, deviation and corrective action handling, change control, supplier qualification, batch record review, material release, training records, and quality agreements with manufacturing partners. If you outsource manufacturing, you still own product quality. A CDMO can execute work, but it cannot remove your responsibility to understand and govern the product.
Fix Unproven Supply Chain & Critical Raw Material Security
The fourth fix is supply chain readiness. A promising product can stall if a single raw material, plasmid, resin, cell line, single-use component, reagent, vial, stopper, or testing vendor cannot support the clinical schedule. Investors know that early teams often focus on process performance and overlook procurement lead times. A fragile supply chain turns a technical plan into a scheduling risk.
Build a critical material list and rank items by risk. Review sole-source exposure, grade, origin, release testing, change notification rights, storage requirements, shelf life, lead time, and substitution options. If a material is research-grade today but must move to clinical-grade supply, document the change plan. If a supplier cannot provide documentation that supports regulatory filing needs, that supplier becomes a funding concern.
Supply chain readiness also includes vendor governance. Your data room should show vendor selection criteria, quality agreements, material specifications, purchase timing, and backup plans for high-risk inputs. If no backup supplier exists, explain the mitigation plan rather than hiding the gap. Investors prefer a known constraint with a costed plan over a late surprise that threatens the trial start.
Fix Incomplete Regulatory CMC Strategy And Comparability Data
The fifth fix is your regulatory CMC strategy. Investors want to see that your manufacturing changes, analytical plan, stability program, and supply chain decisions fit the Investigational New Drug (IND) or clinical trial application path. If your CMC plan is separate from the regulatory plan, diligence teams will notice. The most fundable story connects development choices to regulatory expectations.
Comparability is often where teams underestimate the work. If you change scale, site, process parameters, formulation, container closure, analytical methods, or critical raw materials, you may need data showing that the post-change product remains comparable to prior material. The amount of work depends on the product type, stage, change, and risk. Your Series B materials should name expected changes and explain the testing strategy that supports them.
Stability is part of the same story. Investors want to know whether your shelf-life plan supports manufacturing timing, shipping, site activation, dosing, and backup inventory. A short or poorly supported shelf life can create operational pressure across the trial. A credible stability protocol, with time points, storage conditions, assays, acceptance criteria, and decision rules, gives investors a clearer view of clinical readiness.
Build A Credible CMC Timeline Before Fundraising Starts
CMC fixes rarely fit into a few rushed weeks before diligence. Early-stage teams often underestimate the time needed to establish analytical methods, stability protocols, supply relationships, documentation, and manufacturing slots. A 9–18 month planning window is common for meaningful CMC repair, depending on modality, outsourcing needs, and the number of open gaps. If you wait until investors ask, you are already negotiating from a weaker position.
Create a CMC workplan that starts with the next clinical milestone and works backward. Include manufacturing campaigns, method development, method qualification, raw material ordering, stability pulls, release testing, regulatory writing, quality review, tech transfer, and batch disposition. Tie each task to an owner, decision point, cost range, and risk rating. This makes the plan easier for management, board members, and investors to evaluate.
Your timeline should separate must-fix items from items that can mature after Series B. A must-fix item is one that could delay the trial, trigger a regulatory question, compromise product quality, or make the budget unreliable. A later item may be important for Phase 2 expansion, process yield, or commercial cost of goods, but not required before the next financing. Investors respond better when the team shows sequencing discipline rather than a long list of disconnected CMC tasks.
Prepare A CMC-Safe Series B Data Room
A Series B data room should let investors answer basic manufacturing and control questions without chasing your team for every document. The goal is not volume. The goal is traceability from product understanding to process control, quality governance, clinical supply, and regulatory strategy. If the data room feels disorganized, investors may assume the underlying CMC operation is disorganized too.
Include a concise CMC summary that explains product format, manufacturing process, current scale, intended clinical scale, release strategy, stability status, quality system maturity, vendor roles, and major open risks. Then support that summary with source documents. Useful materials include process descriptions, batch records or batch summaries, certificates of analysis, method summaries, specifications, stability protocols, deviation summaries, vendor agreements, tech-transfer plans, comparability plans, and regulatory CMC sections where available.
Do not bury unresolved issues. Put open CMC risks into a risk register with likelihood, impact, owner, mitigation, cost, and timing. Investors do not expect perfection, but they expect control. A data room that names the gaps and shows the repair plan can protect trust during diligence.
Show Investors That CMC Spending Protects Valuation
Many startups hesitate to spend Series A cash on CMC because discovery and clinical data feel more urgent. That instinct is understandable, but it can backfire before Series B. If investors believe the next dollar must repair basic manufacturing controls before it can advance the asset, they will price that risk into the round. CMC readiness can protect valuation by reducing uncertainty around timing, quality, and execution.
Your pitch deck should include one clear CMC slide, not a dense appendix that appears only after diligence begins. The slide should show the current manufacturing state, next clinical supply need, completed risk reductions, remaining CMC work, budget, timeline, and decision points. Use plain labels: process, analytics, quality, supply, regulatory, stability, comparability. This helps investors see CMC as managed execution rather than hidden technical debt.
Link every CMC investment to a financing or development milestone. A method qualification may support release confidence. A supplier qualification may protect clinical start timing. A comparability plan may reduce regulatory uncertainty after scale-up. When each spend has a purpose, CMC becomes part of the value story rather than a cost center.
How To Audit Your CMC Readiness Before Series B
A practical audit starts with five questions. Can you manufacture enough product for the next clinical plan? Can you test it with fit-for-purpose analytical methods? Can your quality system support GMP clinical supply? Can your suppliers deliver critical materials on time? Can your regulatory CMC story explain process changes, stability, and comparability?
Score each area as ready, partially ready, or not ready. Then assign actions that remove the largest investor risks first. If manufacturing scale is uncertain, run engineering or demonstration work before the raise. If assays are immature, prioritize method qualification and specification rationale. If vendor control is thin, complete supplier qualification and quality agreements before investors request them.
Bring cross-functional owners into the audit. CMC readiness is not only a manufacturing task; it touches regulatory affairs, quality assurance, clinical operations, finance, program management, and executive leadership. A founder or chief executive officer should be able to explain the top CMC risks without handing the entire topic to a consultant. Investors want confidence that leadership understands the operational path, not just the science.
What Are The Most Common CMC Gaps Before Series B?
- Lack of scalable manufacturing process
- Incomplete analytical method validation
- Absence of GMP quality systems
- Insufficient stability and comparability data
- Unsecured supply chain for critical materials
Make CMC The Part Of The Deal That Holds Up Under Pressure
Before Series B, CMC readiness should give investors a straight answer to one concern: can this company make controlled clinical material without preventable delays? Fix the manufacturing process, analytical methods, GMP-aligned quality system, supply chain, and regulatory CMC strategy before the diligence clock starts. Build a timeline that shows owners, costs, milestones, and risk reductions. Put the right documents in the data room and turn your CMC work into a clear valuation story. When your science is strong and your manufacturing plan can stand up to questioning, you give investors fewer reasons to discount the round.
References:
- FDA Office of Pharmaceutical Quality Annual Report
- L.E.K. Consulting, “CMC Readiness: The New Imperative for Biotechs”
- BioSpace, “Before Seeking Series B, Biotechs Must Tackle CMC Readiness”.
Maurizio Chiriva Internati (DBSc, PhDs) is a cancer immunologist and biotech entrepreneur with 20+ years in immuno-oncology. Co-founder and former CEO of Kiromic BioPharma (NASDAQ: KRBP), he has led AI-driven target discovery and translational programs, and has served on faculty at MD Anderson and Texas Tech.
